Top PLR Content Directory Australia

Friday, September 23, 2016

Samsca

Samsca is a brand name of tolvaptan, approved by the FDA in the following formulation(s):

SAMSCA (tolvaptan - tablet; oral)

Manufacturer: OTSUKA AMERICA PHARM

Approval date: May 19, 2009

Strength(s): 15MG, 30MG ^[RLD]

Has a generic version of Samsca been approved?

No. There is currently no therapeutically equivalent version of Samsca available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Samsca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Benzoheterocyclic compounds
Patent 5,753,677
Issued: May 19, 1998
Inventor(s): Ogawa; Hidenori & Miyamoto; Hisashi & Kondo; Kazumi & Yamashita; Hiroshi & Nakaya; Kenji & Komatsu; Hajime & Tanaka; Michinori & Kora; Shinya & Tominaga; Michiaki & Yabuuchi; Yoichi
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Patent expiration dates:
- May 19, 2015
  ✓
  Patent use: METHOD OF TREATING HYPONATREMIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- May 19, 2014 - NEW CHEMICAL ENTITY

Has a generic version of Comtan been approved?

No. There is currently no therapeutically equivalent version of Comtan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Comtan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmacologically active catechol derivatives
Patent 5,446,194
Issued: August 29, 1995
Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
Assignee(s): Orion-yhtyma Oy
A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
Patent expiration dates:
- October 19, 2013
  ✓
  Drug substance

Oral compacted composition comprising catechol derivatives
Patent 6,599,530
Issued: July 29, 2003
Inventor(s): Kari; Vahervuo
Assignee(s): Orion Corporation
The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and croscarmellose sodium. The composition is premised on the discovery that croscarmellose sodium increases the release rate of entacapone or nitecapone from an oral compacted composition. Preferably the amount of croscarmellose sodium in the composition is at least 6% by weight, preferably from about 8% to about 16% by weight, especially from about 10% to about 14% by weight.
Patent expiration dates:
- September 14, 2018
  ✓
  Patent use: TREATMENT OF PARKINSON'S DISEASE
  ✓
  Drug product

Has a generic version of Stalevo 100 been approved?

No. There is currently no therapeutically equivalent version of Stalevo 100 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stalevo 100. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmacologically active catechol derivatives
Patent 5,446,194
Issued: August 29, 1995
Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
Assignee(s): Orion-yhtyma Oy
A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
Patent expiration dates:
- October 19, 2013
  ✓
  Drug substance

Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Patent 6,500,867
Issued: December 31, 2002
Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
Assignee(s): Orion Corporation
An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Patent expiration dates:
- June 29, 2020
  ✓
  Patent use: TREATMENT OF PARKINSON'S DISEASE
  ✓
  Drug product

Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
Patent 6,797,732
Issued: September 28, 2004
Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
Assignee(s): Orion Corporation
An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Patent expiration dates:
- June 29, 2020
  ✓
  Drug product

Has a generic version of ConZip been approved?

No. There is currently no therapeutically equivalent version of ConZip available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ConZip. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Extended release composition containing Tramadol
Patent 7,858,118
Issued: December 28, 2010
Inventor(s): Deboeck; Arthur M. & Vanderbist; Francis & Sereno; Antonio
Assignee(s): Galephar Pharmaceutical Research, Inc.
An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.
Patent expiration dates:
- April 11, 2022
  ✓
  Patent use: USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
  ✓
  Drug product

Has a generic version of Clobex been approved?

A generic version of Clobex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Clobex and have been approved by the FDA:

clobetasol propionate lotion; topical

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: December 4, 2008

Strength(s): 0.05% ^[AB]

clobetasol propionate shampoo; topical

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: June 7, 2011

Strength(s): 0.05% ^[AB]

clobetasol propionate spray; topical

Manufacturer: PADDOCK LLC

Approval date: June 16, 2011

Strength(s): 0.05% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clobex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
Patent 5,972,920
Issued: October 26, 1999
Inventor(s): Seidel; William E.
Assignee(s): Dermalogix Partners, Inc.
One or more formulations for treating psoriasis and other skin disorders characterized by redness, itching, flaking, scaling, and plaque-type growth. The formulation includes a carrier component, one or more active ingredient components, and a surfactant component. The carrier preferably includes an alcohol in substantially equal volume with isopropyl myristate. The active ingredient component preferably includes a superpotent or high-potency corticosteroid such as clobetasol propionate, an anti-flaking ingredient such as zinc pyrithione, or a combination of the two. It may also include an anti-fungal compound. The surfactant component preferably includes an alkyl sulfate such as sodium lauryl sulfate. The formulations made by applied topically either in spray form or as a direct-contact liquid.
Patent expiration dates:
- February 12, 2018
  ✓
  Drug product

Composition and method for treatment of psoriasis
Patent 5,990,100
Issued: November 23, 1999
Inventor(s): Rosenberg; E. William & Glenn; Thomas M. & Skinner, Jr.; Robert B. & Noah; Patricia W.
Assignee(s): Panda Pharmaceuticals, L.L.C.
The University of Tennessee Research Corporation
Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.
Patent expiration dates:
- March 24, 2018
  ✓
  Patent use: TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
  ✓
  Drug product

Topically applicable O/W emulsions having high glycol content and at least one biologically active agent
Patent 6,106,848
Issued: August 22, 2000
Inventor(s): Preuilh; Isabelle & Willcox; Nathalie
Assignee(s): Centre International de Recherches Dermatologiques
Stable, topically applicable oil-in-water bioaffecting emulsions having intermediate viscosity, characteristically ranging from 3 to 10 Pa.multidot.s, comprise (a) from 30% to 50% by weight of at least one pro-penetrating glycol, (b) at least one emulsifying agent, advantageously an anionic amphiphilic polymer, and (c) at least one biologically active agent, for example an active agent that modulates skin differentiation and/or proliferation and/or pigmentation, an anti-inflammatory, an antibacterial, an antifungal, etc.
Patent expiration dates:
- September 22, 2017

Foaming composition for washing and treating hair and/or scalp based on an active principle
Patent 7,316,810
Issued: January 8, 2008
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterized in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- June 17, 2019
  ✓
  Drug product

Foaming compositions for hair care
Patent 7,700,081
Issued: April 20, 2010
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- January 3, 2022
  ✓
  Patent use: TOPICAL TREATMENT OF SCALP PSORIASIS

Foaming composition for washing and treating hair and/or scalp based on an active principle
Patent 8,066,975
Issued: November 29, 2011
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterized in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- June 17, 2019
  ✓
  Drug product

Foaming compositions for hair care
Patent 8,066,976
Issued: November 29, 2011
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- June 17, 2019
  ✓
  Drug product

Has a generic version of Reclast been approved?

No. There is currently no therapeutically equivalent version of Reclast available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reclast. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Substituted alkanediphosphonic acids and pharmaceutical use
Patent 4,939,130
Issued: July 3, 1990
Inventor(s): Jaeggi; Knut A. & Widler; Leo
Assignee(s): Ciba-Geigy Corporation
Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.
Patent expiration dates:
- September 2, 2012
  ✓
  Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  ✓
  Drug substance
  ✓
  Drug product
- March 2, 2013
  ✓
  Pediatric exclusivity

Pharmaceutical products comprising bisphosphonates
Patent 7,932,241
Issued: April 26, 2011
Inventor(s): Glausch; Alexandra & Löffler; Rolf & Sigg; Juergen
Assignee(s): Novartis AG
A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Patent expiration dates:
- February 5, 2028
  ✓
  Drug product
- August 5, 2028
  ✓
  Pediatric exclusivity

Method of administering bisphosphonates
Patent 8,052,987
Issued: November 8, 2011
Inventor(s): Horowitz; Zebulun D. & Richardson; Peter C. & Trechsel; Ulrich
Assignee(s): Novartis Pharmaceuticals Corporation
The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
Patent expiration dates:
- March 19, 2024
  ✓
  Patent use: TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

Related Exclusivities

Exclusivity expiration dates:
- August 17, 2010 - TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- October 16, 2010 - PEDIATRIC EXCLUSIVITY
- February 17, 2011 - PEDIATRIC EXCLUSIVITY
- December 19, 2011 - TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- March 15, 2012 - TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
- May 29, 2012 - PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Has a generic version of Clarinex-D 12 Hour been approved?

No. There is currently no therapeutically equivalent version of Clarinex-D 12 Hour available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clarinex-D 12 Hour. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

8-chloro-6,11-dihydro-11- ] (4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Patent 6,100,274
Issued: August 8, 2000
Inventor(s): Kou; Jim H.
Assignee(s): Schering Corporation
Stable pharmaceutical compositions containing 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cycloheptic[1,2-b ]pyridine("DCL") and a DCL protective amount of a pharmaceutically acceptable basic salt such as calcium dibasic phosphate and an amount of at least one disintegrant, preferably two disintegrates such as microcrystalline cellulose and starch sufficient to provide dissolution of at least about 80% by weight of the pharmaceutical composition in about 45 minutes and suitable for oral administration to treat allergic reactions in mammals such as man are disclosed.
Patent expiration dates:
- July 7, 2019
  ✓
  Drug product
- January 7, 2020
  ✓
  Pediatric exclusivity

Extended release oral dosage composition
Patent 6,709,676
Issued: March 23, 2004
Inventor(s): Wing-Kee Philip; Cho
Assignee(s): Schering Corporation
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Patent expiration dates:
- February 18, 2021
  ✓
  Patent use: ALLERGIC RHINITIS
  ✓
  Drug product

Compositions of descarboethoxyloratadine
Patent 7,214,683
Issued: May 8, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Drug product
- June 30, 2015
  ✓
  Pediatric exclusivity

Methods for the treatment of allergic rhinitis
Patent 7,214,684
Issued: May 8, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
- June 30, 2015
  ✓
  Pediatric exclusivity

Extended release oral dosage composition
Patent 7,618,649
Issued: November 17, 2009
Inventor(s): Cho; Wing-Kee Philip
Assignee(s): Schering Corporation
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Patent expiration dates:
- December 19, 2020
  ✓
  Patent use: A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
  ✓
  Drug product
- June 19, 2021
  ✓
  Pediatric exclusivity

Friday, September 23, 2016

Samsca

SAMSCA (tolvaptan - tablet; oral)

Has a generic version of Samsca been approved?

Related Patents

Related Exclusivities

See also...

Comtan

COMTAN (entacapone - tablet; oral)

Has a generic version of Comtan been approved?

Related Patents

See also...

Stalevo 100

STALEVO 100 (carbidopa; entacapone; levodopa - tablet; oral)

Has a generic version of Stalevo 100 been approved?

Related Patents

See also...

ConZip

CONZIP (tramadol hydrochloride - capsule, extended release; oral)

Has a generic version of ConZip been approved?

Related Patents

See also...

Clobex

CLOBEX (clobetasol propionate - lotion; topical)

CLOBEX (clobetasol propionate - shampoo; topical)

CLOBEX (clobetasol propionate - spray; topical)

Has a generic version of Clobex been approved?

clobetasol propionate lotion; topical

clobetasol propionate shampoo; topical

clobetasol propionate spray; topical

Related Patents

See also...

Reclast

RECLAST (zoledronic acid - injectable; iv (infusion))

Has a generic version of Reclast been approved?

Related Patents

Related Exclusivities

See also...

Clarinex-D 12 Hour

CLARINEX-D 12 HOUR (desloratadine; pseudoephedrine sulfate - tablet, extended release; oral)

Has a generic version of Clarinex-D 12 Hour been approved?

Related Patents

See also...